SELECT * FROM `stock_list` WHERE `symbol` = "PARD" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='PARD' AND exchange = 'OTCPK' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "PARD" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 PARD (Poniard Pharmaceuticals) Cash Conversion Cycle
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Cash Conversion Cycle

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Cash Conversion Cycle : 0.00 (As of Sep. 2011)


View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Poniard Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2011 was 0.
Poniard Pharmaceuticals's Days Inventory for the three months ended in Sep. 2011 was 0.
Poniard Pharmaceuticals's Days Payable for the three months ended in Sep. 2011 was 0.
Therefore, Poniard Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2011 was 0.00.


Poniard Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Poniard Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals Cash Conversion Cycle Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Poniard Pharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, Poniard Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Cash Conversion Cycle falls into.



Poniard Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Poniard Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2010 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

Poniard Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Sep. 2011 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poniard Pharmaceuticals  (OTCPK:PARD) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Poniard Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines